Treats obsessions and compulsions. ANDA 211364, held by Leading Pharma. Clomipramine Hydrochloride.
As of Nov 21, 2026, ANDA 211364 (Clomipramine Hydrochloride), held by Leading Pharma, was first approved by FDA on Feb 7, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clomipramine Hydrochloride capsules, USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are egodystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 7, 2020 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters